GR 113808 Fundamentals Explained
GR 113808 Fundamentals Explained
Blog Article
quinupristin/dalfopristin will improve the level or result of alfentanil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Mysterious.
quinupristin/dalfopristin will enhance the stage or result of eucalyptus by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Not known.
quinupristin/dalfopristin will improve the level or impact of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
quinupristin/dalfopristin will increase the amount or outcome of vinblastine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unknown.
quinupristin/dalfopristin will improve the amount or impact of darunavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
quinupristin/dalfopristin will boost the level or effect of nilotinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
quinupristin/dalfopristin will improve the level or result of oxybutynin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unknown.
Prescription drugs that have to have prior authorization. This restriction necessitates that distinct clinical requirements be achieved just before the acceptance of the prescription.
quinupristin/dalfopristin will boost the degree or influence of ketoconazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unknown.
Keep an eye on Intently (1)quinupristin/dalfopristin raises amounts of vanzacaftor/tezacaftor/deutivacaftor by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
Minimal (one)quinupristin/dalfopristin will improve the amount or effect of estradiol vaginal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Mysterious.
quinupristin/dalfopristin will enhance the level or result of buprenorphine, extensive-acting injection by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Watch Intently. Individuals who transfer to buprenorphine extended-acting injection from transmucosal buprenorphine coadministered with CYP3A4 inhibitors need to be monitored to make certain buprenorphine plasma degrees are adequate.
Medicine that have action therapy connected with Every prescription. This restriction ordinarily calls AZ-23 for that particular standards be fulfilled before approval for the prescription.
quinupristin/dalfopristin will minimize the level or outcome of estrogens conjugated synthetic by altering intestinal flora. Applies only to oral sorts of hormone. Reduced risk of contraceptive failure. Use Caution/Observe.